Opinion: How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process
The press release issued by pharmaceutical companies Eisai and Biogen on Sept. 27 might someday be remembered as the beginning of a revolution in Alzheimer’s diagnosis and treatment.
Years and years of failed Alzheimer’s trials created, and then fortified, doubts about whether drugs that attacked amyloid, a brain protein linked to Alzheimer’s disease, were a valid approach to its treatment. Those doubts may have been quelled.
